CLINICAL EVALUATION OF CEFTIZOXIME IN THE PEDIATRIC INFECTIONS

Ceftizoxime (FK 749, CZX) was evaluated in 24 children with a suspicion of bacterial infection.Of the 17 confirmed bacterial infections, 16 were shown to be effective (effective rate, 94.1%).Thedi agnosis included acute pharyngitis (2), pneumonia (6), staphylococcal empyema (1), cervical purulent ly...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1982/01/25, Vol.35(1), pp.1-8
Main Authors: MASHIKO, JIN, MEGURO, HIDENORI, ZAWA, SHIN-ICHOI, OGO, TOMOKOT, NONAKA, CHIZURU, HIRAIWA, MIKIO, FUJI, RYOCHI
Format: Article
Language:Japanese
Subjects:
Age Factors
Bacterial Infections - drug therapy
Bacterial Infections - metabolism
Cefotaxime - adverse effects
Cefotaxime - analogs & derivatives
Cefotaxime - metabolism
Cefotaxime - therapeutic use
Ceftizoxime
Child
Child, Preschool
Drug Evaluation
Female
Humans
Infant
Male
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ceftizoxime (FK 749, CZX) was evaluated in 24 children with a suspicion of bacterial infection.Of the 17 confirmed bacterial infections, 16 were shown to be effective (effective rate, 94.1%).Thedi agnosis included acute pharyngitis (2), pneumonia (6), staphylococcal empyema (1), cervical purulent lymphadenitis (2), acute enterocolitis (2), acute pyelonephritis (1), S S S S (1) and suspected septicemia (2).The etiologic pathogens recovered were Streptococcus anginosus (1), Streptococcus pneumoniae (1), Staphylococcus aureus (2), Haemophilus influenzae (3), enteropathogenic Escherichia coli (1) etc.A case of suspected Pseudomon2s aeruginosa septicemia was not effectively treated with CZX. The serum half-life of CZX was 1.36 hours after intravenous bolus injection.A cerebrospinal fluid level of CZX was 6.2 mcg/ml 1 hour after intravenous bolus injection of 1 g (23.8 mg/kg) in a child with inflamed meninges. No severe adverse reaction was encountered with the CZX therapy.The data suggest that CZX is an excellent candidate for the first choice parenteral antibiotic in the pediatric infections.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.35.1